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Mutations in GMPPA Cause a Glycosylation Disorder
Characterized by Intellectual Disability
and Autonomic Dysfunction
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J. Christopher Hennings,2 Antje K. Huebner,2 Ammi Grahn,5 Janine Reunert,6 Gudrun Nu¨rnberg,7
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Emile Van Schaftingen,5 Ingo Kurth,2 Angela Huebner,1,* and Christian A. Hu¨bner2,*
In guanosine diphosphate (GDP)-mannose pyrophosphorylase A (GMPPA), we identified a homozygous nonsense mutation that segre-
gated with achalasia and alacrima, delayed developmental milestones, and gait abnormalities in a consanguineous Pakistani pedigree.
Mutations in GMPPA were subsequently found in ten additional individuals from eight independent families affected by the combina-
tion of achalasia, alacrima, and neurological deficits. This autosomal-recessive disorder shows many similarities with triple A syndrome,
which is characterized by achalasia, alacrima, and variable neurological deficits in combination with adrenal insufficiency. GMPPA is a
largely uncharacterized homolog of GMPPB. GMPPB catalyzes the formation of GDP-mannose, which is an essential precursor of glycan
moieties of glycoproteins and glycolipids and is associated with congenital and limb-girdle muscular dystrophies with hypoglycosyla-
tion of a-dystroglycan. Surprisingly, GDP-mannose pyrophosphorylase activity was unchanged and GDP-mannose levels were strongly
increased in lymphoblasts of individuals with GMPPAmutations. This suggests that GMPPA might serve as a GMPPB regulatory subunit
mediating feedback inhibition of GMPPB instead of displaying catalytic enzyme activity itself. Thus, a triple-A-like syndrome can be
added to the growing list of congenital disorders of glycosylation, in which dysregulation rather than mere enzyme deficiency is the
basal pathophysiological mechanism.In the present study, we investigated a consanguineous
Pakistani family (family A) with three siblings who suffered
from alacrima and progressive feeding difficulties—
including dysphagia and episodes of regurgitation, which
developed within the first year of life—but showed no
signs of adrenal insufficiency. All procedures were in accor-
dance with the ethical standards of the responsible com-
mittee on human experimentation, and proper written
informed consent was obtained. Further examination
revealed a functional constriction of the gastric cardia
(achalasia), which required surgery. All affected individuals
presented with delayed developmental milestones, intel-
lectual disability, and gait abnormalities (Figure 1A and
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The Americunaffected, consistent with autosomal-recessive inheri-
tance. The considerable clinical overlap with triple A
syndrome (MIM 231550), which is characterized by acha-
lasia, congenital absence of tear flow (alacrima), adrenal
insufficiency, and progressive neurologic dysfunction,
prompted us to sequence AAAS (MIM 605378), the only
known gene associated with triple A syndrome.1–3
Because no mutation was identified in the coding region
of AAAS, we performed a genome-wide linkage scan in the
family by using the Affymetrix Genome-Wide Human SNP
Array 6.0. We calculated LOD scores by using the program
ALLEGRO4 and assuming autosomal-recessive inheritance
with full penetrance and a disease allele frequency of
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Figure 1. Loss-of-Function Mutations in GMPPA Cause Intellectual Disability with Autonomic Dysfunction
(A) Frontal and lateral views of the affected family members in our index family from Pakistan.
(B) Pedigree and haplotype analysis of the index family. The disease-associated region on 2q36 is shown in red. The position of GMPPA is
between SNPs rs2141817 and rs9288554. Electropherograms show the identified mutation for individual family members.
(C) Localization of the variants identified in all families investigated.
(D) GMPPA abundance in protein lysates of either lymphoblastoid cell lines (left) or fibroblasts (right) obtained from affected individuals
or a healthy proband. Actin served as a loading control.
(E) Transfection of COS-7 cells with wild-type Myc-tagged GMPPA yielded a diffuse cytoplasmic staining, which was altered upon trans-
fection of the p.Gly182Asp and p.Thr334Pro variants. The scale bar represents 20 mm.and 9, thus further excluding AAAS, which maps to 12q13,
as the underlying disease-associated gene (Figure S1, avail-
able online). The 3 Mb chromosome 2 region, with a
maximum LOD score of 3.13, was flanked by markers
rs754752 and rs17288923. For the 500 kb chromosome 9
region, a maximum LOD score of 3.09 was observed
between rs10965932 and rs7022766.728 The American Journal of Human Genetics 93, 727–734, OctoberFor whole-exome sequencing, we fragmented 1 mg of
DNA from individual II:2 by using sonification technology
(Covaris). The fragments were end repaired and adaptor
ligated, including the incorporation of sample index barc-
odes. After size selection, the library was subjected to the
enrichment process with the SeqCap EZ Human Exome
Library v.2.0 (Roche NimbleGen). A total of four samples3, 2013
were pooled and sequenced on two lanes of an Illumina
HiSeq 2000 sequencing instrument with the use of two
paired-end 100 bp sequences, resulting in ~39 million
reads on target with a minimum of 303 coverage for
94% of the target sequences. SNPs and short indels were
called with SAMtools.5 Focusing on the linkage intervals
on chromosomes 2 and 9 (Figure 1), we filtered for homo-
zygous variants not present in dbSNP (build 134) or the
1000 Genomes database (build 20110521) and for variants
that were seen five times or fewer in our in-house exome
database (n ~ 200). The final list contained only two
variants. The first, nonsynonymous change c.19C>T
(p.Pro7Ser) (RefSeq accession number NM_057094.1) in
CRYBA2 (MIM 600836), was later identified as the known
variant rs141631259, which has a reported European pop-
ulation frequency of 2.3% in the National Heart, Lung, and
Blood Institute (NHLBI) Exome Sequencing Project Exome
Variant Server (build ESP6500). The second variant, homo-
zygous nonsense mutation c.295C>T (p.Arg99*) (RefSeq
NM_013335.3) in guanosine diphosphate (GDP)-mannose
pyrophosphorylase A (GMPPA), was absent from genomic
variation databases. This mutation was subsequently
verified by Sanger sequencing (Figure 1B).
Having identified a mutation in GMPPA as the likely
underlying genetic defect in the Pakistani family, we
screened 63 additional families affected by a combination
of alacrima and achalasia but without evidence of a muta-
tion in AAAS. The study was approved by the local ethics
committee (Medical Faculty, Technical University Dresden;
EK820897). Twenty-six individuals also suffered from adre-
nal insufficiency. These individuals with suspected triple A
syndromewere collected at theChildren’s Hospital of Tech-
nical University Dresden and originate from the following
countries: Germany (n¼ 21), Turkey (n¼ 12), Great Britain
(n ¼ 5), the Netherlands (n ¼ 4), United States (n ¼ 4),
Croatia (n ¼ 2), Australia (n ¼ 2), France (n ¼ 2), United
Arab Emirates (n ¼ 1), Austria (n ¼ 1), Czech Republic
(n ¼ 1), Israel (n ¼ 1), Italy (n ¼ 1), Japan (n ¼ 1), Morocco
(n¼ 1), Poland (n¼ 1), Russia (n¼ 1), Slovakia (n¼ 1), and
Tunisia (n ¼ 1). Twenty-four percent of the individuals
derived from consanguineous parents, and 60% derived
from nonconsanguineous parents. For 16% of the individ-
uals, it was unclear whether the parents were consanguin-
eous or not. From eight families, we identified ten individ-
uals with homozygous mutations in GMPPA. Of note,
none of these individuals displayed adrenal insufficiency.
An overviewon the clinical and genetic findings for these
affected individuals is given in Table 1. The mutational
spectrum included one frameshift mutation (c.210delA
[p.Ala71Profs*19]), one nonsense mutation (c.642G>A
[p.Trp214*]), one splice-site mutation (c.993þ1G>A), and
five missense mutations (c.545G>A [p.Gly182Asp],
c.1000A>C [p.Thr334Pro], c.1001C>T [p.Thr334Met],
c.1169G>C [p.Arg390Pro], and c.1202A>C [p.Asn401Thr])
(Figure 1CandFigure S2).Noneof the variantswere listed in
dbSNP (build137), the1000GenomesProject, or theNHLBI
Exome Variant Server.The AmericImmunoblot analysis of either lymphoblastoid cell lines
or fibroblasts of individuals with a homozygous missense
mutation in GMPPA revealed that these affected individ-
uals had lower levels of GMPPA than did control samples
(Figure 1D), indicating that the variant transcript or pro-
teinmight have had reduced stability. Whereas COS-7 cells
transfected with wild-type Myc-tagged GMPPA showed an
intense cytoplasmic labeling, Myc-tagged GMPPA variants
p.Gly182Asp and p.Thr334Pro displayed weak signal
intensity and altered localization (Figure 1E). No staining
was observed for cells transfected with the p.Arg99* and
p.Ala71* variants mimicking the p.Ala71Profs*19 alter-
ation (data not shown). Taken together, these findings—
the mode of inheritance together with the mutational
spectrum—strongly suggest that loss of function in
GMPPA is the underlying mechanism of the disorder.
Human GMPPA encodes GMPPA, a 420 aa protein
(RefSeq NP_037467.2) with known domains in InterPro.
The predicted nucleotidyltransferase domain (amino acids
3–194 [Pfam ID PF00483]) is shared by a wide range of
enzymes that transfer nucleotides onto phosphosugars.6
The hexapep domain (amino acids 286–319 [Pfam ID
PF00132]) is likewise found in several members of the
transferase families.7 The closest homolog of GMPPA in
the human genome is GMPPB, which shares an identity
of 32% at the protein level and a similarity of 49% (GMPPB
isoform 1, RefSeq NP_037466.2).
GMPPB catalyzes the synthesis of GDP-mannose from
mannose-1-phosphate and guanosine triphosphate
(GTP). GDP-mannose serves as a key component of both
N-glycan and, via dolichol-P-mannose, O-glycan chains
in glycoproteins.8 Of note, mutations in GMPPB have
recently been identified to cause congenital and limb-
girdle muscular dystrophies with hypoglycosylation of
a-dystroglycan.9 Most plasma membrane and secretory
proteins undergo N-glycosylation while they mature in
the lumen of the endoplasmic reticulum (ER) and in Golgi
cisternae. In N-linked glycosylation, a branched oligosac-
charide including nine mannose residues is built on a
dolichol lipid anchor present in the ER membrane before
being transferred to an asparagine residue of a nascent
protein. Incorporation of mannose into O-glycosylated
proteins likewise requires GDP-mannose for the biosyn-
thesis of dolichol-P-mannose. GDP-mannose is also used
for glycosylphosphatidylinositol (GPI)-anchored proteins
that are tethered to the outer leaflet of the plasma
membrane. The yeast homolog of GDP-mannose pyro-
phosphorylase, VIG9 (vanadate-resistant and immature
glycosylation, also termed PSA1, SRB1, and MPG1), was
identified by a positive-selection screen with sodium
orthovanadate, a substance that is less toxic in glycosyla-
tion-deficient yeast.10–12 In a screen for hypoosmotic
fragility, another yeast strain carrying a mutation in VIG9
was identified, and it was speculated that defective glyco-
sylation affected the cell-wall integrity of the yeast and
led to reduced stability.13,14 In contrast, the total knockout
of this gene was lethal in yeast.11,15an Journal of Human Genetics 93, 727–734, October 3, 2013 729
Table 1. GMPPA Mutations Identified and Clinical Presentation of the 13 Affected Individuals
Family A Family B Family C Family D Family E Family F Family G Family H Family I
1 2 3 4 5 6 7 8 9 10 11 12 13
Ethnicity Pakistani Pakistani Pakistani Arabic Arabic Turkish Kosovan Pakistani Palestinian Palestinian Dominican Arabic Moroccan
Consanguinity yes yes yes yes yes yes unknown yes NR NR yes yes yes
Sex male male female male male female male female female female female female female
Age at exam
(years)
12 9 7 17 8 17.6 21.2 20.8 9.2 3.7 10.7 6 2.4
Mutation
Location exon 5 exon 5 exon 5 exon 12 exon 12 exon 13 exon 12 exon 13 exon 7 exon 7 exon 4 exon 8 intron 11
cDNA
mutation
c.295C>T c.295C>T c.295C>T c.1000A>C c.1000A>C c.1202A>C c.1001C>T c.1169G>C c.545G>A c.545G>A c.210delA c.642G>A c.993þ1G>A
Protein
alteration
p.Arg99* p.Arg99* p.Arg99* p.Thr334Pro p.Thr334Pro p.Asn401Thr p.Thr334Met p.Arg390Pro p.Gly182Asp p.Gly182Asp p.Ala71Profs*19 p.Trp214* -
Type homozygous homozygous homozygous homozygous homozygous homozygous homozygous homozygous homozygous homozygous homozygous homozygous homozygous
Cardinal Symptoms
Age of onset birth birth birth - - birth birth birth birth birth birth birth birth
Achalasia yes yes yes yes - yes yes yes yes no yes yes yes
Achalasia age
of onset
3 months 1 year 1 year - - 7 years 2 years birth 6 months - 2.5 months 3 months 6 months
Alacrima yes yes yes yes yes yes yes yes yes yes yes yes yes
Alacrima age
of onset
birth birth birth - - birth birth birth birth birth 6 years 3 months birth
Adrenal
insufficiency
no no no no no no no no no no no no no
Epidermal Symptoms
Hyperkeratosis yes yes yes no - no - no no no no no no
Neurological Symptoms
Intellectual
disability
yes yes yes yes - yes yes yes yes yes yes yes unknown
Milestones delayed delayed delayed delayed delayed delayed delayed delayed delayed delayed delayed delayed delayed
Muscular
hypotonia
no no no yes - no - yes yes yes no - no
Gait
abnormalities
ataxia no no - - yes spasticity - no no yes spasticity no
(Continued on next page)
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Table 1. Continued
Family A Family B Family C Family D Family E Family F Family G Family H Family I
1 2 3 4 5 6 7 8 9 10 11 12 13
Babinski no no no - - no - no no no no no no
Hyperreflexia no no no no - no yes no no no no yes no
Hyporeflexia no no no no - no - no no no - no no
Nasal speech no no no no - no - yes yes yes no speech - no
Sensory
impairment
no yes no yes - no - no no no no no no
Hearing
impairment
no no no no - no yes - yes yes - no no
Speech delay yes yes yes - - yes yes - yes yes no speech - yes
Ptosis no yes no - - no - - no no no - no
Autonomic Nervous System Symptoms
Sweating normal normal normal normal - normal - normal decreased decreased no normal normal
Postural
hypotension
no no no no - no - yes (mild) yes yes no no no
Ocular Symptoms
Visual
problems
no no no no - yes - no yes yes yes no no
Nystagmus no no no no - no - yes no no yes no no
Strabism yes no no no - yes - yes no no no no no
Anisocoria no no no yes - yes - yes no no no no no
The following abbreviation is used: NR, not reported.
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Figure 2. GDP-Mannose Levels in Lymphoblasts of Affected
Individuals and Controls
Neutralized perchloric extracts prepared from cultures of Epstein-
Barr virus (EBV)-transformed lymphoblasts were run on high-
performance liquid chromatography22 with a modified gradient
to enhance separation of NDP-sugars. Results are expressed per
mg of cell protein. Intracellular GDP-mannose was significantly
higher (***p < 0.001) in EBV-transformed lymphoblasts from
individual 4 (p.Thr334Pro) and individual 6 (p.Asn401Thr) than
in four healthy controls. The statistics were calculated with one-
way ANOVA combined with Tukey’s multiple-comparison test.This background implied that a glycosylation defect
might be expected in our individuals with a defect in
GMPPA. Congenital disorders of glycosylation (CDGs) are
grouped into two different types.16–18 Whereas type I
CDGs are characterized by defects in lipid-linked oligosac-
charide synthesis and transfer, type II CDGs alter the pro-
cessing of protein-bound sugar chains. Although there is a
wide clinical spectrum, developmental delay appears to be
one of the most consistent findings. Defects in O-glycosyl-
ation usually have a clinical outcome that is distinct from
N-glycosylation defects and rather cause muscular dystro-
phy, bone or cartilage disorders, or extracellular matrix
defects.
So far, two subtypes of CDGs have been linked to the
enzymatic pathway that generates GDP-mannose, which
is synthesized from fructose-6-phosphate via mannose-6-
phosphate andmannose-1-phosphate in a three-step enzy-
matic reaction. Alterations in the enzymes catalyzing steps
one and two of this reaction cause autosomal-recessive
CDG type Ib (also known as MPI-CDG [MIM 602579])
and CDG type Ia (also known as PMM2-CDG [MIM
212065]), respectively. MPI-CDG, caused by mutations in
MPI (MIM 154550), leads to chronic diarrhea, cyclic
vomiting, and enteropathy with villus atrophy, hypoglyce-
mia, and facultative hepatic fibrosis. However, mental and
motor development is normal. In MPI-CDG, GDP-
mannose is depleted and can be corrected by external
mannose supplementation.19 PMM2-CDG is caused by
mutations in PMM2 (MIM 601785) and is the most
frequent subtype of the glycosylation disorders. Individ-732 The American Journal of Human Genetics 93, 727–734, Octoberuals with the ‘‘classic’’ form of PMM2-CDG have psycho-
motor retardation, convergent strabismus, cerebellar
hypoplasia, seizures, and a coagulopathy.20 Common for
both PMM2-CDG andMPI-CDG is the GDP-mannose defi-
ciency that leads to detectable hypoglycosylation of
numerous glycoproteins in the serum or fibroblasts of
affected individuals.21 In contrast, GDP-mannose levels
were drastically higher in lymphoblast samples from indi-
viduals with a GMPPA defect than in those from control
samples (Figure 2), whereas other nucleoside diphosphate
(NDP)-sugars were unchanged (data not shown). The
galactose-1-phosphate level in red blood cells of individual
6 was within normal limits as well (data not shown).
Because of the increased levels of GDP-mannose, it is
tempting to speculate that a mannose-depleted diet might
be a therapeutic choice in individuals with a GMPPA
defect. The increase in GDP-mannose levels might cause
imbalances in glycosylation reactions by favoring reac-
tions displaying a high Km for this NDP-sugar or by inhib-
iting enzymes with the use of other NDP-sugars.23 Howev-
er, the affected individuals and control subjects showed
similar N-glycosylation profiles, both for transferrin glyco-
sylation (Table S1) and for N-glycans derived from either
total serum protein or immunoglobulin G (Figure S3).
Moreover, serum Apo-CIII glycosylation did not differ be-
tween controls and our individuals (data not shown). In
addition, the activity of GDP-mannose pyrophosphorylase
in lymphoblasts of two affected individuals did not show
significant alterations (Table S2). Although our analysis
of serum proteins did not display any clear alteration of
N-glycosylation, the change induced by GDP-mannose
overload might only be significant in restricted cell types
or affect other glycosylation types (O-glycosylation, C-
glycosylation, and GPI anchor synthesis) than those inves-
tigated here. Elevated GDP-mannose levels could also lead
to strong perturbations in the levels of other guanine nu-
cleotides (e.g., depletion of GTP), which could have far-
reaching consequences not linked to glycosylation (e.g.,
dysfunction of G-proteins).
The elevated levels of GDP-mannose in GMPPA-defi-
cient cells indicate that GMPPAmight serve as a regulatory
subunit and allow allosteric feedback inhibition of GMPPB
byGDP-mannose.8 GMPPA and GMPPB are indeed present
in roughly equal amounts in native GDP-mannose pyro-
phosphorylase.24 Only GMPPB displays catalytic activ-
ity,8 although GMPPA is able to bind GDP-mannose.24
This suggests that after a gene duplication event, GMPPA
underwent mutations that converted its encoded protein
to an allosteric subunit. Interestingly, sequence alignments
indicate that compared to GMPPBs and other NDP-sugar
pyrophosphorylases belonging to the same family,
GMPPAs from all species are characterized by a 2 aa inser-
tion (Pro11-Gln12 in the human enzyme) in a highly
conserved motif that borders the catalytic pocket and
binds the nucleotide substrate in homologous en-
zymes.25,26 This insertion presumably inactivated the
ancestral catalytic site, converting it to an allosteric site.3, 2013
An analogous situation is found with the plant enzyme
ADP-glucose pyrophosphorylase, which consists of two
types of homologous subunits, only one of which is
endowed with catalytic activity, whereas the other plays
a role in allosteric regulation.26
In view of the broad expression of the mouse ortholog
of GMPPA (Figure S4; for methods, see Rust et al.27 and
Hermey et al.28), the clinical symptoms of GMPPA-muta-
tion-positive persons with developmental delay, alacrima,
and achalasia imply that GMPPA is particularly relevant
in neurons and autonomic nerve fibers innervating the
distal esophageal sphincter or the lacrimal glands. Of
note, individuals with congenital and limb-girdle
muscular dystrophies with hypoglycosylation of a-dystro-
glycan due to defects in GMPPB also develop neurological
symptoms.9 So far, none of the individuals with a muta-
tion in GMPPA revealed signs of an adrenal insufficiency
as described for triple A syndrome. Thus, persons
suffering from alacrima and achalasia without adrenal
insufficiency should primarily be sequenced for muta-
tions in GMPPA.
The phenotype of individuals with GMPPA mutations
shares aspects with hereditary sensory and autonomic
neuropathies (HSANs), characterized by sensory loss or,
as in the case of HSAN type III (MIM 223900), mainly
autonomic dysfunction.29,30 Prominent autonomic
dysfunction is also found in Fabry disease (MIM 301500),
Tangier disease (MIM 205400), multiple endocrine
neoplasia type IIB (MIM 162300), and mtDNA depletion
syndrome 6 (MIM 256810).31 Further investigations are
needed for addressing the role of GMPPA in autonomic
ganglia neurons. Whether this disorder, similarly to
MPI-CDG, might be a potentially treatable hereditary
condition, e.g., by a mannose-depleted diet, will be an
important issue for the future.Supplemental Data
Supplemental Data include four figures and two tables and
can be found with this article online at http://www.cell.com/
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